Caftor

Study	Exclusion reasons	Rmk	Reference
Boyd, 2025	inadequate or absent control group	EXCLUDED: Comparison of outcomes after Highly Effective Modulator Therapy (HEMT) versus non HEMT, that could include other CFTR modulators (not specified) => No adequate control group.	Boyd, H. J. Cyst. Fibrosis 2025; 24:S12-. 10.1016/j.jcf.2025.03.525
Barnidge, 2025	data not abstractable	EXCLUDED: Preterm birth rates were higher among FwCF taking CFTR modulators compared to FwCF not taking modulators (20% vs. 6.7%, P < 0.001) => Raw data not provided => OR cannot be calculated.	Barnidge, M. J. Cyst. Fibrosis 2025; 24:S460-. 10.1016/S1569-1993(25)02376-8
Naehrig, 2022	data not abstractable	EXCLUDED: Outcomes were provided for only 7 babies (among 11 pregnancies), and the distribution of these babies across the exposure groups is not provided => Denominators not available.	Naehrig, S. J. Cyst. Fibrosis 2022; 21:S32-. 10.1016/S1569-1993(22)00744-5
Scott (ETI), 2025	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Obstetric and Neonatal Outcomes provided for all females with Cystic Fibrosis (fwCF), whatever the treatments (81% Elexacaftor/Tezacaftor/Ivacaftor (ETI)).	Scott BJOG 2025; : 10.1111/1471-0528.70075